4.28
price up icon0.94%   0.04
pre-market  Pre-market:  4.27   -0.01   -0.23%
loading
4 D Molecular Therapeutics Inc stock is traded at $4.28, with a volume of 449.73K. It is up +0.94% in the last 24 hours and down -9.32% over the past month. 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
See More
Previous Close:
$4.24
Open:
$4.24
24h Volume:
449.73K
Relative Volume:
0.52
Market Cap:
$198.17M
Revenue:
$20.72M
Net Income/Loss:
$-100.84M
P/E Ratio:
-1.609
EPS:
-2.66
Net Cash Flow:
$-78.56M
1W Performance:
+3.38%
1M Performance:
-9.32%
6M Performance:
-73.66%
1Y Performance:
-85.44%
1-Day Range:
Value
$4.165
$4.40
1-Week Range:
Value
$3.7258
$4.40
52-Week Range:
Value
$3.7258
$36.25

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name
Name
4 D Molecular Therapeutics Inc
Name
Phone
(510) 505-2680
Name
Address
5858 HORTON STREET #455, EMERYVILLE
Name
Employee
227
Name
Twitter
Name
Next Earnings Date
2024-12-13
Name
Latest SEC Filings
Name
FDMT's Discussions on Twitter

Compare FDMT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
FDMT
4 D Molecular Therapeutics Inc
4.28 198.17M 20.72M -100.84M -78.56M -2.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-13-25 Downgrade BMO Capital Markets Outperform → Market Perform
Nov-21-24 Initiated Morgan Stanley Underweight
Sep-23-24 Downgrade Cantor Fitzgerald Overweight → Neutral
Apr-15-24 Initiated Barclays Overweight
Feb-07-24 Resumed Goldman Buy
Oct-26-23 Initiated RBC Capital Mkts Outperform
Oct-24-23 Initiated Cantor Fitzgerald Overweight
Oct-18-23 Upgrade Leerink Partners Market Perform → Outperform
Jul-05-23 Initiated Chardan Capital Markets Buy
Jan-30-23 Initiated BMO Capital Markets Outperform
Nov-18-22 Initiated H.C. Wainwright Buy
Nov-15-22 Upgrade Goldman Neutral → Buy
Aug-12-22 Downgrade SVB Leerink Outperform → Mkt Perform
Jun-22-22 Initiated Jefferies Buy
Jan-04-22 Initiated SVB Leerink Outperform
Jan-05-21 Initiated BofA Securities Buy
Jan-05-21 Initiated Evercore ISI Outperform
Jan-05-21 Initiated Goldman Neutral
View All

4 D Molecular Therapeutics Inc Stock (FDMT) Latest News

pulisher
Mar 13, 2025

Proficio Capital Partners LLC Has $111,000 Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

4D Molecular Therapeutics’ SWOT analysis: gene therapy firm faces durability hurdles - Investing.com

Mar 12, 2025
pulisher
Mar 11, 2025

Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News

Mar 11, 2025
pulisher
Mar 11, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $40.00 by Analysts at Bank of America - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

4DMT enrolls first patient in late-stage trial for its retinal eye disease therapy -March 10, 2025 at 09:31 am EDT - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

4D Molecular announces first patients enrolled in 4FRONT-1 Phase 3 trial - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

4D Molecular Therapeutics Enrolls First Patients in Phase 3 Clinical Trial for 4D-150, Targeting Wet Age-Related Macular Degeneration - Nasdaq

Mar 10, 2025
pulisher
Mar 10, 2025

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD - GlobeNewswire

Mar 10, 2025
pulisher
Mar 10, 2025

FDMT4D Molecular Therapeutics Inc. Latest Stock News & Market Updates - StockTitan

Mar 10, 2025
pulisher
Mar 09, 2025

Rhumbline Advisers Acquires 3,675 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by New York State Common Retirement Fund - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

FY2025 EPS Estimates for FDMT Boosted by Cantor Fitzgerald - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Analysts Issue Forecasts for FDMT Q1 Earnings - Defense World

Mar 07, 2025
pulisher
Mar 05, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given New $28.00 Price Target at Chardan Capital - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.

Mar 04, 2025
pulisher
Mar 04, 2025

Deeper Dive: Understanding 4D Molecular Therapeutics Inc (FDMT) Through its Various Ratios - The Dwinnex

Mar 04, 2025
pulisher
Mar 04, 2025

4D Molecular price target lowered to $35 from $39 at RBC Capital - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

Chardan Trims Price Target on 4D Molecular Therapeutics to $28 From $30, Keeps Buy Rating - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

4D Molecular Therapeutics’ (FDMT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given New $35.00 Price Target at Royal Bank of Canada - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Moderna (NASDAQ:MRNA) and 4D Molecular Therapeutics (NASDAQ:FDMT) Head to Head Review - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

4D Molecular price target lowered to $28 from $30 at Chardan - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics - Benzinga

Mar 03, 2025
pulisher
Mar 03, 2025

RBC Lowers Price Target on 4D Molecular Therapeutics to $35 From $39, Keeps Outperform, Speculative Risk - Marketscreener.com

Mar 03, 2025
pulisher
Mar 02, 2025

4D Molecular Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance UK

Mar 02, 2025
pulisher
Mar 01, 2025

4D Molecular Therapeutics Reports Strong Clinical Progress and Financial Position - TipRanks

Mar 01, 2025
pulisher
Mar 01, 2025

FDMT stock touches 52-week low at $4.4 amid sharp annual decline - Investing.com Australia

Mar 01, 2025
pulisher
Feb 28, 2025

4D Molecular Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView

Feb 28, 2025
pulisher
Feb 28, 2025

4D Molecular Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 28, 2025
pulisher
Feb 28, 2025

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times

Feb 28, 2025
pulisher
Feb 28, 2025

4D Molecular Therapeutics Reports Positive Clinical Data for 4D-150 in Wet AMD and DME, Outlines Strategic Pipeline and Financial Position - Nasdaq

Feb 28, 2025
pulisher
Feb 28, 2025

Can 4DMT's $505M Cash Runway and Promising Eye Disease Data Overcome Rising Losses? - StockTitan

Feb 28, 2025
pulisher
Feb 27, 2025

Spotlight On February 2025's Promising Penny Stocks - Simply Wall St

Feb 27, 2025
pulisher
Feb 27, 2025

4D Molecular Therapeutics (FDMT) Projected to Post Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 25, 2025

4D Molecular Therapeutics, Inc. (FDMT) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire

Feb 25, 2025
pulisher
Feb 23, 2025

Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Price Target at $32.13 - Defense World

Feb 23, 2025
pulisher
Feb 20, 2025

4D Molecular Therapeutics’ (FDMT) Sell (D-) Rating Reiterated at Weiss Ratings - Defense World

Feb 20, 2025
pulisher
Feb 19, 2025

4DMT to Participate in Upcoming Investor Conferences - GlobeNewswire

Feb 19, 2025
pulisher
Feb 19, 2025

4D Molecular's March Investor Showcase: What These Two Major Conference Appearances Signal - StockTitan

Feb 19, 2025
pulisher
Feb 18, 2025

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression - Seeking Alpha

Feb 18, 2025
pulisher
Feb 17, 2025

4D Molecular Therapeutics' SWOT analysis: gene therapy firm's stock faces durability test - Investing.com

Feb 17, 2025
pulisher
Feb 15, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given New $30.00 Price Target at Chardan Capital - MarketBeat

Feb 15, 2025
pulisher
Feb 14, 2025

Peapod Lane Capital LLC Purchases New Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat

Feb 14, 2025
pulisher
Feb 13, 2025

Jefferies cuts 4D Molecular Therapeutics target to $40 - MSN

Feb 13, 2025
pulisher
Feb 12, 2025

FDMT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Stockholders to Contact the Firm! - ACCESS Newswire

Feb 12, 2025
pulisher
Feb 12, 2025

FDMT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Investors to Contact the Firm! - ACCESS Newswire

Feb 12, 2025
pulisher
Feb 12, 2025

FDMT stock touches 52-week low at $4.42 amid sharp annual decline - Investing.com India

Feb 12, 2025
pulisher
Feb 12, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Lowered to $30.00 at Chardan Capital - Defense World

Feb 12, 2025
pulisher
Feb 11, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc.FDMT - PR Newswire

Feb 11, 2025
pulisher
Feb 11, 2025

Gene Therapy In CNS Disorder Treatment Market Size Report 2032 | - openPR

Feb 11, 2025

4 D Molecular Therapeutics Inc Stock (FDMT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):